IMMUNONEUTRALIZATION OF ENDOGENOUS GLUCAGON WITH MONOCLONAL GLUCAGON ANTIBODY NORMALIZES HYPERGLYCEMIA IN MODERATELY STREPTOZOTOCIN-DIABETIC RATS
IMMUNONEUTRALIZATION OF ENDOGENOUS GLUCAGON WITH MONOCLONAL GLUCAGON ANTIBODY NORMALIZES HYPERGLYCEMIA IN MODERATELY STREPTOZOTOCIN-DIABETIC RATS
复制标题
DOI：
10.1007/bf00400461
复制
发表时间：
1994-10-01
期刊：
影响因子：
8.2
通讯作者：
HOLST, JJ
中科院分区：
文献类型：
--
作者：
BRAND, CL;ROLIN, B;HOLST, JJ
胰高血糖素在糖尿病高血糖中的作用一直存在争议，因为选择性胰高血糖素缺乏难以产生。我们开发了高容量（40 nmol/ml），高亲和力（0.6 nmol/ml）。10(11) l/mol)单克隆胰高血糖素抗体（Glu-mAb），并给大鼠静脉注射（4 ml/kg），研究选择性胰高血糖素缺乏对血糖的影响。对照组接种针对三硝基苯的单克隆抗体。Glu-mAb完全消除正常大鼠2.86 nmol/kg胰高血糖素的高血糖作用(p
The role of glucagon in diabetic hyperglycaemia has been a matter of controversy because of difficulties in the production of selective glucagon deficiency. We developed a high-capacity (40 nmol/ml), high-affinity (0.6 . 10(11) l/mol) monoclonal glucagon antibody (Glu-mAb) and gave i.v, injections (4 ml/kg) to rats in order to study the effect of selective glucagon deficiency on blood glucose. Controls received a mAb against trinitrophenyl. Glu-mAb completely abolished the hyperglycaemic effect of 2.86 nmol/kg glucagon in normal rats (p